Regeneron Pharma (REGN) Posts Q1 Loss of $0.49, Wider than Views
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $834.04 +0.90%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 loss of ($0.49), $0.13 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $112.2 million versus the consensus estimate of $117.02 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
